[{"id":"79649cc6-d582-4cf7-94a7-6b84b6103cab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04901702","created_at":"2021-05-25T18:52:49.387Z","updated_at":"2025-02-25T12:28:07.986Z","phase":"Phase 1/2","brief_title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","source_id_and_acronym":"NCT04901702","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" EWSR1 • FLI1","pipe":"","alterations":" ","tags":["EWSR1 • FLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"e26feb64-5ce0-4689-b638-098d6bd0300f","acronym":"E-VIRTUE","url":"https://clinicaltrials.gov/study/NCT06041503","created_at":"2025-02-25T12:29:47.446Z","updated_at":"2025-02-25T12:29:47.446Z","phase":"Phase 2","brief_title":"Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)","source_id_and_acronym":"NCT06041503 - E-VIRTUE","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-24"},{"id":"6076406a-9463-43ad-ba76-13f9a5a2bd1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01445288","created_at":"2021-01-18T05:59:39.581Z","updated_at":"2025-02-25T13:39:05.076Z","phase":"","brief_title":"Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors","source_id_and_acronym":"NCT01445288","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" VEGFA • TNFA","pipe":"","alterations":" ","tags":["VEGFA • TNFA"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 12/05/2006","start_date":" 12/05/2006","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"e1eec305-12a1-4b55-aca1-9621bccaf5e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05836324","created_at":"2023-05-01T15:04:34.613Z","updated_at":"2025-02-25T14:03:30.395Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05836324","lead_sponsor":"Incyte Corporation","biomarkers":" HER-2 • BRAF • ER • PGR • ROS1","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["HER-2 • BRAF • ER • PGR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INCA33890"],"overall_status":"Recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 07/24/2023","start_date":" 07/24/2023","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2026","study_completion_date":" 12/24/2026","last_update_posted":"2025-02-19"},{"id":"759667ed-3d93-4013-b60b-a6259ed986b1","acronym":"MCC-21113","url":"https://clinicaltrials.gov/study/NCT05316129","created_at":"2022-04-07T13:56:37.707Z","updated_at":"2025-02-25T15:12:44.059Z","phase":"Phase 1","brief_title":"Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer","source_id_and_acronym":"NCT05316129 - MCC-21113","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" PD-L1 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["PD-L1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e liraltagene autoleucel (lira-cel)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-13"},{"id":"99c4032a-3714-4351-a6af-2208fcba233e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684368","created_at":"2021-01-19T20:47:18.675Z","updated_at":"2025-02-25T15:11:50.245Z","phase":"Phase 2","brief_title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","source_id_and_acronym":"NCT04684368","lead_sponsor":"Children's Oncology Group","biomarkers":" NF1","pipe":" | ","alterations":" AFP elevation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cyclophosphamide • ifosfamide • etoposide IV • mesna • thiotepa • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 07/13/2021","start_date":" 07/13/2021","primary_txt":" Primary completion: 12/21/2029","primary_completion_date":" 12/21/2029","study_txt":" Completion: 12/21/2029","study_completion_date":" 12/21/2029","last_update_posted":"2025-02-13"},{"id":"c6ceadea-5216-44bc-b521-a84f4461c694","acronym":"","url":"https://clinicaltrials.gov/study/NCT03389802","created_at":"2021-01-18T16:43:48.401Z","updated_at":"2025-02-25T15:10:43.667Z","phase":"Phase 1","brief_title":"Phase I Study of APX005M in Pediatric Central Nervous System Tumors","source_id_and_acronym":"NCT03389802","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" TMB • TNFA • CXCL8 • CD4","pipe":"","alterations":" ","tags":["TMB • TNFA • CXCL8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sotigalimab (PYX-107)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-13"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"5416351c-6e6b-41af-9e81-7fd2a0e36c13","acronym":"GETUG 13","url":"https://clinicaltrials.gov/study/NCT00104676","created_at":"2021-01-18T00:20:19.559Z","updated_at":"2025-02-25T16:35:55.671Z","phase":"Phase 3","brief_title":"Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors","source_id_and_acronym":"NCT00104676 - GETUG 13","lead_sponsor":"UNICANCER","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • ifosfamide • oxaliplatin • etoposide IV • bleomycin"],"overall_status":"Completed","enrollment":" Enrollment 263","initiation":"Initiation: 11/26/2003","start_date":" 11/26/2003","primary_txt":" Primary completion: 03/29/2012","primary_completion_date":" 03/29/2012","study_txt":" Completion: 02/08/2023","study_completion_date":" 02/08/2023","last_update_posted":"2025-02-06"},{"id":"75e429d1-288b-438c-890d-57227288a551","acronym":"","url":"https://clinicaltrials.gov/study/NCT00436254","created_at":"2021-01-18T01:32:21.652Z","updated_at":"2025-02-25T16:35:57.454Z","phase":"Phase 1","brief_title":"Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer","source_id_and_acronym":"NCT00436254","lead_sponsor":"University of Washington","biomarkers":" HER-2 • MUC16","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AST-301 • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 10/01/2001","start_date":" 10/01/2001","primary_txt":" Primary completion: 03/01/2010","primary_completion_date":" 03/01/2010","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-06"},{"id":"e3328e0d-a58a-4276-b607-b9374b9c681f","acronym":"AcceleRET Lung","url":"https://clinicaltrials.gov/study/NCT04222972","created_at":"2021-01-18T14:26:40.385Z","updated_at":"2025-02-25T16:37:43.151Z","phase":"Phase 3","brief_title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04222972 - AcceleRET Lung","lead_sponsor":"Hoffmann-La Roche","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Gavreto (pralsetinib)"],"overall_status":"Completed","enrollment":" Enrollment 223","initiation":"Initiation: 07/24/2020","start_date":" 07/24/2020","primary_txt":" Primary completion: 01/27/2025","primary_completion_date":" 01/27/2025","study_txt":" Completion: 01/27/2025","study_completion_date":" 01/27/2025","last_update_posted":"2025-02-06"},{"id":"a960e964-3a5f-401a-844c-ae8dd61b3da6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213704","created_at":"2023-12-06T19:15:43.766Z","updated_at":"2025-02-25T16:51:56.748Z","phase":"Phase 2","brief_title":"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213704","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 08/23/2017","start_date":" 08/23/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 10/08/2025","study_completion_date":" 10/08/2025","last_update_posted":"2025-02-04"},{"id":"e098103f-75c1-4aa9-b386-41c1d51fb602","acronym":"MATCH","url":"https://clinicaltrials.gov/study/NCT03155620","created_at":"2021-01-18T15:33:32.929Z","updated_at":"2025-02-25T16:51:52.930Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","source_id_and_acronym":"NCT03155620 - MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2316","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-04"},{"id":"4f82c263-5191-440b-b1f7-d234cfb0ecd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05969860","created_at":"2023-08-01T15:10:04.032Z","updated_at":"2025-02-25T17:39:06.594Z","phase":"Phase 2","brief_title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients with Advanced Cancer","source_id_and_acronym":"NCT05969860","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 08/23/2023","start_date":" 08/23/2023","primary_txt":" Primary completion: 06/14/2025","primary_completion_date":" 06/14/2025","study_txt":" Completion: 06/14/2025","study_completion_date":" 06/14/2025","last_update_posted":"2025-01-29"},{"id":"2c66d4b7-1c2e-4cd1-a61a-2f452cfb4042","acronym":"","url":"https://clinicaltrials.gov/study/NCT06470464","created_at":"2025-02-26T14:17:59.459Z","updated_at":"2025-02-26T14:17:59.459Z","phase":"Phase 2","brief_title":"Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor","source_id_and_acronym":"NCT06470464","lead_sponsor":"Shandong First Medical University","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • epirubicin • thalidomide"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/11/2021","start_date":" 11/11/2021","primary_txt":" Primary completion: 06/16/2024","primary_completion_date":" 06/16/2024","study_txt":" Completion: 06/16/2024","study_completion_date":" 06/16/2024","last_update_posted":"2024-06-24"},{"id":"4898b5ad-3c9a-468d-8fed-e1f7bd83f3ff","acronym":"CARVac","url":"https://clinicaltrials.gov/study/NCT04503278","created_at":"2021-05-18T06:52:33.666Z","updated_at":"2025-02-25T16:25:57.832Z","phase":"Phase 1","brief_title":"A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors","source_id_and_acronym":"NCT04503278 - CARVac","lead_sponsor":"BioNTech Cell \u0026 Gene Therapies GmbH","biomarkers":" AFP • CLDN6","pipe":" | ","alterations":" CLDN6 expression • CLDN6 positive","tags":["AFP • CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 expression • CLDN6 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BNT211"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 09/16/2020","start_date":" 09/16/2020","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2040","study_completion_date":" 01/01/2040","last_update_posted":"2024-05-31"},{"id":"1ba7d423-e8de-4bf4-9f12-f7ec8c7c5db7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03526250","created_at":"2021-01-18T17:22:05.437Z","updated_at":"2024-07-02T16:35:02.332Z","phase":"Phase 2","brief_title":"Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03526250","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-21"},{"id":"6f199ca7-66c7-422b-8786-948a1a709536","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213678","created_at":"2021-01-18T15:51:26.276Z","updated_at":"2024-07-02T16:35:02.372Z","phase":"Phase 2","brief_title":"Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213678","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • TSC2 • TSC1","pipe":" | ","alterations":" PTEN expression • TSC1 mutation • TSC2 mutation","tags":["PTEN • TSC2 • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression • TSC1 mutation • TSC2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/28/2017","start_date":" 11/28/2017","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-05-21"},{"id":"82dcc018-99ce-47f7-8c3b-045c9ebf3e1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03220035","created_at":"2021-01-18T15:53:33.764Z","updated_at":"2024-07-02T16:35:02.750Z","phase":"Phase 2","brief_title":"Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03220035","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 11/08/2017","start_date":" 11/08/2017","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-05-17"},{"id":"ed745a1a-e25b-481e-9a43-45f739d28d5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04239092","created_at":"2021-01-18T20:36:34.133Z","updated_at":"2024-07-02T16:35:03.671Z","phase":"Phase 1","brief_title":"9-ING-41 in Pediatric Patients With Refractory Malignancies.","source_id_and_acronym":"NCT04239092","lead_sponsor":"Actuate Therapeutics Inc.","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • cyclophosphamide • irinotecan • topotecan • elraglusib (9-ING-41) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-05-15"},{"id":"96e07c94-7a83-4ec3-b148-9faedc5d7126","acronym":"HFB-200301-01","url":"https://clinicaltrials.gov/study/NCT05238883","created_at":"2022-02-14T15:52:46.465Z","updated_at":"2024-07-02T16:35:06.647Z","phase":"Phase 1","brief_title":"A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05238883 - HFB-200301-01","lead_sponsor":"HiFiBiO Therapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • emunkitug (HFB200301)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-01"},{"id":"4649ce0f-4d86-452f-8851-2645fe630f89","acronym":"","url":"https://clinicaltrials.gov/study/NCT05592743","created_at":"2022-10-25T13:56:20.154Z","updated_at":"2024-07-02T16:35:07.258Z","phase":"","brief_title":"Vorasidenib Expanded Access Program","source_id_and_acronym":"NCT05592743","lead_sponsor":"Servier","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Voranigo (vorasidenib)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-04-26"},{"id":"84a8bbc2-ef05-45fb-8d2a-c2429e123035","acronym":"STRIvE-02","url":"https://clinicaltrials.gov/study/NCT04483778","created_at":"2021-01-18T21:31:43.742Z","updated_at":"2024-07-02T16:35:07.947Z","phase":"Phase 1","brief_title":"B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT04483778 - STRIvE-02","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression • CD19 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2024-04-23"},{"id":"89dd2a7f-11f6-4dd3-813c-39c7d1f75e4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01602666","created_at":"2021-01-18T06:51:17.342Z","updated_at":"2024-07-02T16:35:08.661Z","phase":"Phase 2","brief_title":"Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors","source_id_and_acronym":"NCT01602666","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cyclophosphamide • ifosfamide • etoposide IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 262","initiation":"Initiation: 06/27/2012","start_date":" 06/27/2012","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-19"}]